Orexo AB (publ) (ORXOF)

Market Cap	102.35M
Revenue (ttm)	57.68M
Net Income (ttm)	-21.42M
Shares Out	n/a
EPS (ttm)	-0.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,000
Average Volume	2,344
Open	2.900
Previous Close	2.550
Day's Range	2.900 - 2.900
52-Week Range	1.080 - 2.900
Beta	0.74
RSI	47.25
Earnings Date	Oct 23, 2025

About Orexo AB

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Employees: 110
• Stock Exchange: OTCMKTS
• Ticker Symbol: ORXOF

Financial Performance

In 2024, Orexo AB's revenue was 590.00 million, a decrease of -7.64% compared to the previous year's 638.80 million. Losses were -203.00 million, 58.2% more than in 2023.

Financial numbers in SEK